The estimated Net Worth of Stephen F. Mahoney is at least $469 Thousand dollars as of 16 September 2021. Mr Mahoney owns over 5,736 units of Magenta Therapeutics Inc stock worth over $9,985 and over the last 6 years he sold MGTA stock worth over $38,603. In addition, he makes $420,475 as Chief Financial & Operating Officer and Treasurer at Magenta Therapeutics Inc.
Sign up
Mr MBA MGTA stock SEC Form 4 insiders trading
Mr has made over 1 trades of the Magenta Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 5,736 units of MGTA stock worth $38,603 on 16 September 2021.
The largest trade he's ever made was selling 5,736 units of Magenta Therapeutics Inc stock on 16 September 2021 worth over $38,603. On average, Mr trades about 521 units every 0 days since 2018. As of 16 September 2021 he still owns at least 14,264 units of Magenta Therapeutics Inc stock.
You can see the complete history of Mr Mahoney stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Stephen F. Mahoney J.D., MBA biography
Stephen F. Mahoney J.D., MBA is the Chief Financial & Operating Officer and Treasurer at Magenta Therapeutics Inc.
What is the salary of Mr MBA?
As the Chief Financial & Operating Officer and Treasurer of Magenta Therapeutics Inc, the total compensation of Mr MBA at Magenta Therapeutics Inc is $420,475. There are 4 executives at Magenta Therapeutics Inc getting paid more, with Christina Isacson having the highest compensation of $2,277,560.
How old is Mr MBA?
Mr MBA is 50, he's been the Chief Financial & Operating Officer and Treasurer of Magenta Therapeutics Inc since . There are 9 older and 9 younger executives at Magenta Therapeutics Inc. The oldest executive at Magenta Therapeutics Inc is David Scadden, 67, who is the Independent Director.
What's Mr MBA's mailing address?
Stephen's mailing address filed with the SEC is C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139.
Insiders trading at Magenta Therapeutics Inc
Over the last 6 years, insiders at Magenta Therapeutics Inc have traded over $6,775,591 worth of Magenta Therapeutics Inc stock and bought 1,257,000 units worth $10,105,000 . The most active insiders traders include Bruce Booth, Rock Ventures Iv, L.P.Third..., and Jeffrey W. Albers. On average, Magenta Therapeutics Inc executives and independent directors trade stock every 46 days with the average trade being worth of $99,614. The most recent stock trade was executed by Rock Ventures Iv, L.P.Third... on 7 February 2023, trading 3,700,000 units of MGTA stock currently worth $3,071,000.
What does Magenta Therapeutics Inc do?
magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.
What does Magenta Therapeutics Inc's logo look like?
Complete history of Mr Mahoney stock trades at Kiniksa Pharmaceuticals International Plc and Magenta Therapeutics Inc
Magenta Therapeutics Inc executives and stock owners
Magenta Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Christina Isacson,
Chief Business Officer -
Jason Gardner,
President, Chief Executive Officer, Co-Founder, Director -
John Davis,
Chief Medical Officer, Head of Research and Development -
Dr. Jason Gardner Ph.D.,
Co-Founder, CEO, Pres & Director -
Stephen F. Mahoney J.D., MBA,
Chief Financial & Operating Officer and Treasurer -
Anne McGeorge,
Independent Director -
David Scadden,
Independent Director -
Michael Bonney,
Independent Chairman of the Board -
Alexis Borisy,
Independent Director -
Jeffrey Albers,
Independent Director -
Thomas Daniel,
Independent Director -
Bruce Booth,
Independent Director -
Blake Byers,
Independent Director -
Amy Ronneberg,
Independent Director -
Steve Mahoney,
Chief Financial and Operating Officer -
Manisha Pai,
Vice President - Communications and Investor Relations -
Zoran Zdraveski,
Secretary and Chief Legal Officer -
Li Malmberg,
Senior Vice President - Head of Manufacturing -
Kristen Stants,
Chief People Officer -
Cindy Driscoll,
Vice President - Finance -
Dr. Jan Pinkas Ph.D.,
Sr. VP & Head of Translational Sciences -
Catherine Monaghan,
Head of Clinical Devel. Operations -
Kristen Stants,
Chief People Officer -
Lyndsey Scull,
Director of Corp. Communications -
Thomas W. Beetham,
Chief Legal Officer -
Jim Haney,
Sr. Director of Investor Relations -
Dr. Lisa M. Olson Ph.D.,
Head of Research & Chief Scientific Officer -
David Wayne Nichols,
Chief Technical Officer -
Lisa Olson,
See Remarks -
Caren Deardorf,
Chief Commercial Officer -
Venture Fund X, L.P.Atlas V...,
-
Rock Ventures Iv, L.P.Third...,
-
2016 Gp, L.L.C.Gv 2016 Gp, ...,
-
Jason Ryan,
See Remarks -
Venture Fund X, L.P. Atlas,
10% owner -
Stephen F. Mahoney,
See Remarks -
Michael P. Cooke,
Chief Scientific Officer -
Thomas W. Beetham,
See Remarks -
Jeffrey Humphrey,
Chief Medical Officer -
Alison Frances Lawton,
Director -
David Wayne Nichols,
Chief Technical Officer -
Michael Vasconcelles,
Director